Details for Patent: 8,733,341
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,733,341 protect, and when does it expire?
Patent 8,733,341 protects COMBIVENT RESPIMAT, STIOLTO RESPIMAT, STRIVERDI RESPIMAT, and SPIRIVA RESPIMAT, and is included in four NDAs.
Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eleven patent family members in seven countries.
Summary for Patent: 8,733,341
Title: | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Abstract: | An atomizer and a method of dispensing and atomizing fluid into individual containers through a nozzle are proposed, where in order to improve the dosing accuracy, a preliminary amount of fluid, flushing the nozzle, is dispensed before each dose is dispensed. |
Inventor(s): | Boeck; Georg (Laupheim, DE), Spallek; Michael (Ingelheim, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 12/299,650 |
Patent Claim Types: see list of patent claims | Delivery; Device; Formulation; Use; |
Drugs Protected by US Patent 8,733,341
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | COMBIVENT RESPIMAT | albuterol sulfate; ipratropium bromide | SPRAY, METERED;INHALATION | 021747-001 | Oct 7, 2011 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756-001 | May 21, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Boehringer Ingelheim | STRIVERDI RESPIMAT | olodaterol hydrochloride | SPRAY, METERED;INHALATION | 203108-001 | Jul 31, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,733,341
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 10 2006 022 002 | May 10, 2006 |
PCT Information | |||
PCT Filed | April 16, 2007 | PCT Application Number: | PCT/EP2007/003322 |
PCT Publication Date: | November 15, 2007 | PCT Publication Number: | WO2007/128381 |
International Family Members for US Patent 8,733,341
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 483489 | See Plans and Pricing | |||
Canada | 2651190 | See Plans and Pricing | |||
Germany | 102006022002 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |